Mirabegron (Myrbetriq)
Prescription medicine for overactive bladder that is also studied for fat burning, but is not approved for that.

DETAILED OVERVIEW
What is Mirabegron (Myrbetriq)?
Mirabegron (Myrbetriq) is a prescription medicine approved for the symptoms of overactive bladder: in the United States since 2012, and in Europe under the name Betmiga. It acts on a receptor that relaxes the muscle of the bladder and, in brown fat (the body's heat-producing fat), switches on heat production. For this reason it is also studied for fat burning, and it is used off-label.
In studies in healthy adults it switched on the activity of brown fat, and after longer treatment the amount of brown fat and insulin sensitivity increased. Its main risk is strain on the heart and blood vessels: it can raise blood pressure and heart rate. The official prescribing information warns of severe blood pressure rises and a fast heartbeat. It is contraindicated in severe, uncontrolled high blood pressure. It can cause difficulty passing urine and, rarely, severe swelling of the face, lips or tongue. It is not recommended in pregnancy and breastfeeding. WADA does not ban it outright, but several national sports federations treat it as a monitored substance.
Mechanism
Selective β3-adrenoceptor agonist (detrusor + BAT UCP1 induction)
Half-life
~50 hours (once-daily dosing optimal)
Onset time
Detrusor 2-4 h; BAT activation chronic dose 2-4 weeks
Legal status
FDA + EMA Rx (OAB), HU + PL registered. WADA: not explicitly banned, monitored by some national federations.
Mirabegron stands out in community reports as one of the few compounds with actual human evidence for brown adipose tissue (BAT) activation. Users describe it as well tolerated, with a real but mild "background" thermogenic effect that passively contributes to fat loss – notably without any stimulant-like feeling. Reports consistently frame it as a long-game compound rather than a rapid weight-shedding tool.
At higher doses, a noticeable rise in resting heart rate or blood pressure is reported, which is why some accounts mention co-administration with a selective beta-1 blocker; the more pronounced fat-loss effects also tend to appear only at those higher doses. Combining it with cold-exposure protocols is anecdotally said to amplify BAT activation, as both target similar thermogenic pathways.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Hadi FA, Schild A, Hansen MK . Efficacy and Safety of Mirabegron in Males with Overactive Bladder and Lower Urinary Tract Symptoms: Analysis from an Integrated Clinical Trial Database.. Eur Urol Open Sci.
Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elía E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM . Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.. Cell Metab.
Loh RKC, Formosa MF, La Gerche A, Reutens AT, Kingwell BA, Carey AL . Acute metabolic and cardiovascular effects of mirabegron in healthy individuals.. Diabetes Obes Metab.
O'Mara AE, Johnson JW, Linderman JD, Brychta RJ, McGehee S, Fletcher LA, Fink YA, Kapuria D, Cassimatis TM, Kelsey N, Cero C, Sater ZA, Piccinini F, Baskin AS, Leitner BP, Cai H, Millo CM, Dieckmann W, Walter M, Javitt NB, Rotman Y, Walter PJ, Ader M, Bergman RN, Herscovitch P, Chen KY, Cypess AM . Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.. J Clin Invest.
Cypess AM, White AP, Vernochet C et al. . Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat Med. 2013;19(5):635-639..
White WB, Siddiqui E, Tat T, Franks B, Schermer CR . Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.. J Am Soc Hypertens.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Blood pressure elevation, hypertension (dose-dependent, one of the most common and clinically important effects; pre-existing hypertension can worsen)
- Tachycardia, increased resting heart rate, palpitations
- Urinary retention, difficulty voiding, urinary tract infection (from detrusor relaxation, especially with bladder outlet obstruction)
- Headache, dizziness
- Nasopharyngitis, upper respiratory symptoms, dry mouth
- Constipation, nausea, abdominal discomfort
- QTc prolongation at higher doses (ECG monitoring warranted, especially with other QT-prolonging drugs)
- Rare but serious: angioedema (swelling of face, lips, tongue, larynx, with airway-obstruction risk – requires immediate discontinuation)
Contraindications · 7
- Severe, uncontrolled hypertension (>=180/110 mmHg) – absolute contraindication (FDA warning; do not start if blood pressure is uncontrolled)
- Severe renal impairment (ESRD/dialysis) and severe hepatic impairment (Child-Pugh C) – not recommended; dose reduction required in moderate impairment
- Clinically significant bladder outlet obstruction or OAB treated with antimuscarinics – increased urinary retention risk
- Pre-existing tachyarrhythmia, unstable/significant cardiac disease, or known QT prolongation / QT-prolonging drugs – elevated cardiac risk
- Pregnancy and breastfeeding – not recommended (insufficient human safety data)
- Hypersensitivity to mirabegron or excipients, or prior history of angioedema
- Caution with sensitive CYP2D6 substrates (e.g. metoprolol, desipramine) and CYP2D6-inhibiting SSRIs/TCAs – plasma-level increase, dose adjustment may be needed
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Efficacy and Safety of Mirabegron in Males with Overactive Bladder and Lower Urinary Tract Symptoms: Analysis from an Integrated Clinical Trial Database.
Hadi FA, Schild A, Hansen MK
Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.
Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elía E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM
Acute metabolic and cardiovascular effects of mirabegron in healthy individuals.
Loh RKC, Formosa MF, La Gerche A, Reutens AT, Kingwell BA, Carey AL
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.
O'Mara AE, Johnson JW, Linderman JD, Brychta RJ, McGehee S, Fletcher LA, Fink YA, Kapuria D, Cassimatis TM, Kelsey N, Cero C, Sater ZA, Piccinini F, Baskin AS, Leitner BP, Cai H, Millo CM, Dieckmann W, Walter M, Javitt NB, Rotman Y, Walter PJ, Ader M, Bergman RN, Herscovitch P, Chen KY, Cypess AM
Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat
Cypess AM, White AP, Vernochet C et al.
Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.
White WB, Siddiqui E, Tat T, Franks B, Schermer CR
Telegram
Have a question about Mirabegron (Myrbetriq)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.